

CLINICAL CANCER RESEARCH

TABLE OF CONTENTS

HIGHLIGHTS

1215 Selected Articles from This Issue

SPECIAL FEATURES

CCR Translations

1217 **MEK-ing the Most of It: Strategies to Co-target G α q and MAPK in Uveal Melanoma**
Sathya Neelature Sriramareddy and Keiran S.M. Smalley
See related article, p. 1476

CCR Drug Updates

1220 **FDA Approval Summary: Tucatinib for the Treatment of Patients with Advanced or Metastatic HER2-positive Breast Cancer**
Mirat Shah, Suparna Wedam, Joyce Cheng, Mallorie H. Fiero, Huiming Xia, Fang Li, Jianghong Fan, Xinyuan Zhang, Jingyu Yu, Pengfei Song, Wei Chen, Tiffany K. Ricks, Xiao Hong Chen, Kirsten B. Goldberg, Yutao Gong, William F. Pierce, Shenghui Tang, Marc R. Theoret, Richard Pazdur, Laleh Amiri-Kordestani, and Julia A. Beaver

Review

1227 **B7-H3: An Attractive Target for Antibody-based Immunotherapy**
Filippos Kontos, Theodoros Michelakos, Tomohiro Kurokawa, Ananthan Sadagopan, Joseph H. Schwab, Cristina R. Ferrone, and Soldano Ferrone

Perspectives

1236 **Tumor Mutational Burden as a Predictor of Immunotherapy Response: Is More Always Better?**
ACC John H. Strickler, Brent A. Hanks, and Mustafa Khasraw

CLINICAL TRIAL BRIEF REPORT

1242 **Eradication of T-ALL Cells by CD7-targeted Universal CAR-T Cells and Initial Test of Ruxolitinib-based CRS Management**
Shiqi Li, Xinxin Wang, Zhongtao Yuan, Lin Liu, Le Luo, Yu Li, Kun Wu, Jia Liu, Chunhui Yang, Zhimin Li, Duanpeng Wang, Lianjun Shen, Xun Ye, Jiaping He, Cong Han, Youcheng Wang, Dingsong Zhang, Yancheng Dong, Lihua Fang, Yingnian Chen, Martina Sersch, Wei William Cao, and Sanbin Wang

CLINICAL TRIALS: TARGETED THERAPY

1247 **Phase I Study of Everolimus, Letrozole, and Trastuzumab in Patients with Hormone Receptor-positive Metastatic Breast Cancer or Other Solid Tumors**
Alexej Ballhausen, Jennifer J. Wheler, Daniel D. Karp, Sarina A. Piha-Paul, Siqing Fu, Shubham Pant, Apostolia M. Tsimberidou, David S. Hong, Vivek Subbiah, Veronica R. Holley, Helen J. Huang, Abenaa M. Brewster, Kimberly B. Koenig, Nuhad K. Ibrahim, Funda Meric-Bernstam, and Filip Janku

1256 **Phase I and Pharmacologic Study of Olaparib in Combination with High-dose Radiotherapy with and without Concurrent Cisplatin for Non-Small Cell Lung Cancer**
Rosemarie de Haan, Michel M. van den Heuvel, Judi van Diessen, Heike M.U. Peulen, Erik van Werkhoven, Adrianus J. de Langen, Ferry Lalezari, Dick Pluim, Manon Verwijs-Janssen, Conchita Vens, Jan H.M. Schellens, Neeltje Steeghs, Marcel Verheij, and Baukelien van Triest

CLINICAL TRIALS: IMMUNOTHERAPY

1267 **Safety and Clinical Activity of a New Anti-PD-L1 Antibody as Monotherapy or Combined with Targeted Therapy in Advanced Solid Tumors: The PACT Phase Ia/Ib Trial**
Amita Patnaik, Timothy A. Yap, Hyun Cheol Chung, Maria J. de Miguel, Yung-Jue Bang, Chia-Chi Lin, Wu-Chou Su, Antoine Italiano, Kay Hoong Chow, Anna M. Szpurka, Danni Yu, Yumin Zhao, Michelle Carlsen, Shelly Schmidt, Burkhard Vangerow, Leena Gandhi, Xiaojian Xu, and Johanna Bendell

TABLE OF CONTENTS

- 1278** **Vaccine-Induced Intratumoral Lymphoid Aggregates Correlate with Survival Following Treatment with a Neoadjuvant and Adjuvant Vaccine in Patients with Resectable Pancreatic Adenocarcinoma**
Lei Zheng, Ding Ding, Barish H. Edil, Carol Judkins, Jennifer N. Durham, Dwayne L. Thomas II, Katherine M. Bever, Guanglan Mo, Sara E. Solt, Jessica A. Hoare, Raka Bhattacharya, Qingfeng Zhu, Arsen Osipov, Beth Onner, Katrina A. Purtell, Hongyan Cai, Rose Parkinson, Amy Hacker-Prietz, Joseph M. Herman, Dung T. Le, Nilofer S. Azad, Ana M.C. De Jesus-Acosta, Alex B. Blair, Victoria Kim, Kevin C. Soares, Lindsey Manos, John L. Cameron, Martin A. Makary, Matthew J. Weiss, Richard D. Schulick, Jin He, Christopher L. Wolfgang, Elizabeth D. Thompson, Robert A. Anders, Elizabeth Sugar, Elizabeth M. Jaffee, and Daniel A. Laheru
- 1287** **Ipilimumab and Radiation in Patients with High-risk Resected or Regionally Advanced Melanoma**
April K.S. Salama, Manisha Palta, Christel N. Rushing, M. Angelica Selim, Kristen N. Linney, Brian G. Czito, David S. Yoo, Brent A. Hanks, Georgia M. Beasley, Paul J. Mosca, Chelsae Dumbauld, Katelyn N. Steadman, John S. Yi, Kent J. Weinhold, Douglas S. Tyler, Walter T. Lee, and David M. Brizel
- 1296** **Efficacy and Biomarker Analysis of Camrelizumab in Combination with Apatinib in Patients with Advanced Nonsquamous NSCLC Previously Treated with Chemotherapy**
Caicun Zhou, Yina Wang, Jun Zhao, Gongyan Chen, Zhihua Liu, Kangsheng Gu, Meijuan Huang, Jianxing He, Jianhua Chen, Zhiyong Ma, Jifeng Feng, Jianhua Shi, Xinmin Yu, Ying Cheng, Yu Yao, Yuan Chen, Renhua Guo, Xiaoyan Lin, Zhehai Wang, Guanghui Gao, Quanren Wang, Weixia Li, Xinfeng Yang, Lihong Wu, Jun Zhang, and Shengxiang Ren
- 1305** **Molecular Imaging of Prostate Cancer Targeting CD46 Using ImmunoPET**
Sinan Wang, Jun Li, Jun Hua, Yang Su, Denis R. Beckford-Vera, Walter Zhao, Mayuri Jayaraman, Tony L. Huynh, Ning Zhao, Yung-hua Wang, Yangjie Huang, Fujun Qin, Sui Shen, Daniel Gioeli, Robert Dreicer, Renuka Sriram, Emily A. Egusa, Jonathan Chou, Felix Y. Feng, Rahul Aggarwal, Michael J. Evans, Youngho Seo, Bin Liu, Robert R. Flavell, and Jiang He
- 1316** **A Performance Comparison of Commonly Used Assays to Detect RET Fusions**
Soo-Ryum Yang, Umut Aypar, Ezra Y. Rosen, Douglas A. Mata, Ryma Benayed, Kerry Mullaney, Gowtham Jayakumaran, Yanming Zhang, Denise Frosina, Alexander Drilon, Marc Ladanyi, Achim A. Jungbluth, Natasha Rekhtman, and Jaclyn F. Hechtman
- 1329** **Gut Microbiome Components Predict Response to Neoadjuvant Chemoradiotherapy in Patients with Locally Advanced Rectal Cancer: A Prospective, Longitudinal Study**
Yuxi Yi, Lijun Shen, Wei Shi, Fan Xia, Hui Zhang, Yan Wang, Jing Zhang, Yaqi Wang, Xiaoyang Sun, Zhiyuan Zhang, Wei Zou, Wang Yang, Lingyi Zhang, Ji Zhu, Ajay Goel, Yanlei Ma, and Zhen Zhang
- 1341** **Genome Methylation Accurately Predicts Neuroendocrine Tumor Origin: An Online Tool**
Wenzel M. Hackeng, Koen M.A. Dreijerink, Wendy W.J. de Leng, Folkert H.M. Morsink, Gerlof D. Valk, Menno R. Vriens, G. Johan A. Offerhaus, Christoph Geisenberger, and Lodewijk A.A. Brosens
- 1351** **Final Results of the Prospective Biomarker Trial PETra: [¹¹C]-MET-Accumulation in Postoperative PET/MRI Predicts Outcome after Radiochemotherapy in Glioblastoma**
Annekatriin Seidlitz, Bettina Beuthien-Baumann, Steffen Löck, Christina Jentsch, Ivan Platzek, Klaus Zöphel, Annett Linge, Jörg Kotzerke, Jan Petr, Jörg van den Hoff, Jörg Steinbach, Dietmar Krex, Gabriele Schmitz-Schackert, Monique Falk, Michael Baumann, and Mechthild Krause
- 1361** **The Use of Serial Circulating Tumor DNA to Detect Resistance Alterations in Progressive Metastatic Breast Cancer**
A C Saya Jacob, Andrew A. Davis, Lorenzo Gerratana, Marko Velimirovic, Ami N. Shah, Firas Wehbe, Neelima Katam, Qiang Zhang, Lisa Flaum, Kalliopi P. Siziopikou, Leonidas C. Plataniias, William J. Gradishar, Amir Behdad, Aditya Bardia, and Massimo Cristofanilli
- 1371** **Expression of T-Cell Exhaustion Molecules and Human Endogenous Retroviruses as Predictive Biomarkers for Response to Nivolumab in Metastatic Clear Cell Renal Cell Carcinoma**
Miriam Ficial, Opeyemi A. Jegede, Miriam Sant'Angelo, Yue Hou, Abdallah Flaifel, Jean-Christophe Pignon, David A. Braun, Megan Wind-Rotolo, Maura A. Sticco-Ivins, Paul J. Catalano, Gordon J. Freeman, Arlene H. Sharpe, F. Stephen Hodi, Robert J. Motzer, Catherine J. Wu, Michael B. Atkins, David F. McDermott, Sachet A. Shukla, Toni K. Choueiri, and Sabina Signoretti
- 1381** **CamGFR v2: A New Model for Estimating the Glomerular Filtration Rate from Standardized or Non-standardized Creatinine in Patients with Cancer**
Edward H. Williams, Thomas R. Flint, Claire M. Connell, Daniel Giglio, Hassal Lee, Taehoon Ha, Eva Gablenz, Nicholas J. Bird, James M.J. Weaver, Harry Potts, Cameron T. Whitley, Michael A. Bookman, Andy G. Lynch, Hannah V. Meyer, Simon Tavaré, and Tobias Janowitz

TABLE OF CONTENTS

- 1391** **Circulating Tumor Cell Subtypes and T-cell Populations as Prognostic Biomarkers to Combination Immunotherapy in Patients with Metastatic Genitourinary Cancer**
AC Heather J. Chalfin, Tiziano Pramparo, Amir Mortazavi, Scot A. Niglio, Joseph D. Schonhoft, Adam Jendrisak, Yen-Lin Chu, Robin Richardson, Rachel Krupa, Amanda K.L. Anderson, Yipeng Wang, Ryan Dittamore, Sumanta K. Pal, Primo N. Lara, Mark N. Stein, David I. Quinn, Seth M. Steinberg, Lisa M. Cordes, Lisa Ley, Marissa Mallek, Olena Sierra Ortiz, Rene Costello, Jacqueline Cadena, Carlos Diaz, James L. Gulley, William L. Dahut, Howard Streicher, John J. Wright, Jane B. Trepel, Donald P. Bottaro, and Andrea B. Apolo
- 1399** **¹⁷⁷Lu-DOTA-EB-TATE, a Radiolabeled Analogue of Somatostatin Receptor Type 2, for the Imaging and Treatment of Thyroid Cancer**
AC Shilpa Thakur, Brianna Daley, Corina Millo, Craig Cochran, Orit Jacobson, Huiyan Lu, Zhantong Wang, Dale Kiesewetter, Xiaoyuan Chen, Vasyl Vasko, and Joanna Klubo-Gwiezdzinska
- 1410** **Proteasome Inhibition Overcomes ALK-TKI Resistance in *ALK*-Rearranged/*TP53*-Mutant NSCLC via Noxa Expression**
AC Azusa Tanimoto, Shingo Matsumoto, Shinji Takeuchi, Sachiko Arai, Koji Fukuda, Akihiro Nishiyama, Kiyotaka Yoh, Takaya Ikeda, Naoki Furuya, Kazumi Nishino, Yuichiro Ohe, Koichi Goto, and Seiji Yano
- 1421** **Early Discontinuation of Endocrine Therapy and Recurrence of Breast Cancer among Premenopausal Women**
Lindsay J. Collin, Deirdre P. Cronin-Fenton, Thomas P. Ahern, Michael Goodman, Lauren E. McCullough, Lance A. Waller, Anders Kjærsgaard, Per Damkier, Peer M. Christiansen, Bent Ejlersen, Maj-Britt Jensen, Henrik Toft Sørensen, and Timothy L. Lash
- 1429** **Characterization and Clinical Outcomes of DNA Mismatch Repair-deficient Small Bowel Adenocarcinoma**
Alicia Latham, Jinru Shia, Zalak Patel, Diane L. Reidy-Lagunes, Neil H. Segal, Rona Yaeger, Karuna Ganesh, Louise Connell, Nancy E. Kemeny, David P. Kelsen, Jaclyn F. Hechtman, Garrett M. Nash, Philip B. Paty, Ahmet Zehir, Kaitlin A. Tkachuk, Rania Sheikh, Arnold J. Markowitz, Diana Mandelker, Kenneth Offit, Michael F. Berger, Andrea Cercek, Julio Garcia-Aguilar, Leonard B. Saltz, Martin R. Weiser, and Zsofia K. Stadler
- 1438** **Targeted Therapy of *TERT*-Rearranged Neuroblastoma with BET Bromodomain Inhibitor and Proteasome Inhibitor Combination Therapy**
Jingwei Chen, Christopher Nelson, Matthew Wong, Andrew E. Tee, Pei Y. Liu, Ting La, Jamie I. Fletcher, Alvin Kamili, Chelsea Mayoh, Christoph Bartenhagen, Toby N. Trahair, Ning Xu, Nisitha Jayatilleke, Marie Wong, Hui Peng, Bernard Atmadibrata, Belamy B. Cheung, Qing Lan, Tracy M. Bryan, Pieter Mestdagh, Jo Vandesompele, Valerie Combaret, Valentina Boeva, Jenny Y. Wang, Isabelle Janoueix-Lerosey, Mark J. Cowley, Karen L. MacKenzie, Alla Dolnikov, Jinyan Li, Patsie Polly, Glenn M. Marshall, Roger R. Reddel, Murray D. Norris, Michelle Haber, Matthias Fischer, Xu D. Zhang, Hilda A. Pickett, and Tao Liu
- 1452** **Preclinical Characterization of HPN536, a Trispecific, T-Cell-Activating Protein Construct for the Treatment of Mesothelin-Expressing Solid Tumors**
AC Mary Ellen Molloy, Richard J. Austin, Bryan D. Lemon, Wade H. Aaron, Vaishnavi Ganti, Adrie Jones, Susan D. Jones, Kathryn L. Strobel, Purbasa Patnaik, Kenneth Sexton, Laurie Tatalick, Timothy Z. Yu, Patrick A. Baeuerle, Che-Leung Law, and Holger Wesche
- 1463** **Tarloxotinib Is a Hypoxia-Activated Pan-HER Kinase Inhibitor Active Against a Broad Range of HER-Family Oncogenes**
Adriana Estrada-Bernal, Anh T. Le, Andrea E. Doak, Vijaya G. Tirunagaru, Shevan Silva, Matthew R. Bull, Jeff B. Smail, Adam V. Patterson, Chul Kim, Stephen V. Liu, and Robert C. Doebele
- 1476** **Combined Inhibition of G α_q and MEK Enhances Therapeutic Efficacy in Uveal Melanoma**
Tyler D. Hitchman, Gabriella Bayshtok, Emilie Ceraudo, Amanda R. Moore, Cindy Lee, Ruobing Jia, Naitao Wang, Mohini R. Pachai, Alexander N. Shoushtari, Jasmine H. Francis, Youxin Guan, Juliet Chen, Matthew T. Chang, Barry S. Taylor, Thomas P. Sakmar, Thomas Huber, Ping Chi, and Yu Chen
See related commentary, p. 1217
- 1491** **FGFR Inhibition Overcomes Resistance to EGFR-targeted Therapy in Epithelial-like Cutaneous Carcinoma**
Adrià Bernat-Peguera, Juan Navarro-Ventura, Laura Lorenzo-Sanz, Victoria da Silva-Diz, Mattia Bosio, Luis Palomero, Rosa M. Penin, Diana Pérez Sidelnikova, Josep Oriol Bermejo, Miren Taberna, Noelia Vilarino, Josep M. Piulats, Ricard Mesia, Joan Maria Viñals, Eva González-Suárez, Salvador Capella-Gutierrez, Alberto Villanueva, Francesc Viñals, and Purificación Muñoz

TABLE OF CONTENTS

- 1505 High-dose per Fraction Radiotherapy Induces Both Antitumor Immunity and Immunosuppressive Responses in Prostate Tumors**
Lin Lin, Nathanael Kane, Naoko Kobayashi, Evelyn A. Kono, Joyce M. Yamashiro, Nicholas G. Nickols, and Robert E. Reiter
- 1516 The Genetic Evolution of Treatment-Resistant Cutaneous, Acral, and Uveal Melanomas**
Alvin P. Makohon-Moore, Evan J. Lipson, Jody E. Hooper, Amanda Zucker, Jungeui Hong, Craig M. Bielski, Akimasa Hayashi, Collin Tokheim, Priscilla Baez, Rajya Kappagantula, Zachary Kohutek, Vladimir Makarov, Nadeem Riaz, Michael A. Postow, Paul B. Chapman, Rachel Karchin, Nicholas D. Socci, David B. Solit, Timothy A. Chan, Barry S. Taylor, Suzanne L. Topalian, and Christine A. Iacobuzio-Donahue
- 1526 AMG 757, a Half-Life Extended, DLL3-Targeted Bispecific T-Cell Engager, Shows High Potency and Sensitivity in Preclinical Models of Small-Cell Lung Cancer**
AC Michael J. Giffin, Keegan Cooke, Edward K. Lobenhofer, Juan Estrada, Jinghui Zhan, Petra Deegen, Melissa Thomas, Christopher M. Murawsky, Jonathan Werner, Siyuan Liu, Fei Lee, Oliver Homann, Matthias Friedrich, Joshua T. Pearson, Tobias Raum, Yajing Yang, Sean Caenepeel, Jennitte Stevens, Pedro J. Beltran, Jude Canon, Angela Coxon, Julie M. Bailis, and Paul E. Hughes
- 1538 CEACAM7 Is an Effective Target for CAR T-cell Therapy of Pancreatic Ductal Adenocarcinoma**
AC Deepak Raj, Maria Nikolaidi, Irene Garces, Daniela Lorzio, Natalia M. Castro, Sabrina G. Caiafa, Kate Moore, Nicholas F. Brown, Hemant M. Kocher, Xiaobo Duan, Brad H. Nelson, Nicholas R. Lemoine, and John F. Marshall
- 1553 YAP/TAZ Transcriptional Coactivators Create Therapeutic Vulnerability to Verteporfin in EGFR-mutant Glioblastoma**
Krishanthan Vigneswaran, Nathaniel H. Boyd, Se-Yeong Oh, Shoeb Lallani, Andrew Boucher, Stewart G. Neill, Jeffrey J. Olson, and Renee D. Read
- 1570 The Oxford Classic Links Epithelial-to-Mesenchymal Transition to Immunosuppression in Poor Prognosis Ovarian Cancers**
Zhiyuan Hu, Paula Cunnea, Zhe Zhong, Haonan Lu, Oloruntoba I. Osagie, Leticia Campo, Mara Artibani, Katherine Nixon, Jennifer Ploski, Laura Santana Gonzalez, Abdulkhaliq Alsaadi, Nina Wietek, Stephen Damato, Sunanda Dhar, Sarah P. Blagden, Christopher Yau, Joanna Hester, Ashwag Albukhari, Eric O. Aboagye, Christina Fotopoulou, and Ahmed Ahmed
- LETTERS TO THE EDITOR**
- 1580 Plasma Tumor Mutation Burden and Response to Pembrolizumab—Letter**
Zhiqiang Xue, Xueguang Guo, Jiabin Wen, Wenhan Cai, Xinying Xue, Xiaochen Zhao, Jing Zhao, and Yuezhong Bai
- 1581 Plasma Tumor Mutation Burden and Response to Pembrolizumab—Response**
Charu Aggarwal, Jeffrey C. Thompson, and Erica L. Carpenter
- CORRECTION**
- 1582 Correction: A Phase II Study of Abemaciclib in Patients with Brain Metastases Secondary to Hormone Receptor-positive Breast Cancer**
Sara M. Tolaney, Solmaz Sahebjam, Emilie Le Rhun, Thomas Bachelot, Peter Kabos, Ahmad Awada, Denise Yardley, Arlene Chan, Pierfranco Conte, Véronique Diéras, Nancy U. Lin, Melissa Bear, Sonya C. Chapman, Zhengyu Yang, Yanyun Chen, and Carey K. Anders


AC AC icon indicates AuthorChoice

For more information please visit www.aacrjournals.org

TABLE OF CONTENTS

ABOUT THE COVER

The cover shows a section of an invasive breast carcinoma with RET amplification. RET structural variant was not detected. RET immunohistochemistry shows a heterogenous staining pattern. For details, see the article by Yang and colleagues on page 1316 of this issue.



Clinical Cancer Research

27 (5)

Clin Cancer Res 2021;27:1215-1582.

Updated version Access the most recent version of this article at:
<http://clincancerres.aacrjournals.org/content/27/5>

E-mail alerts [Sign up to receive free email-alerts](#) related to this article or journal.

Reprints and Subscriptions To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions To request permission to re-use all or part of this article, use this link <http://clincancerres.aacrjournals.org/content/27/5>. Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.